"Pharmaceutical headline king" Lingbei will lay off 160 people Pharmacy serious overcapacity

(2020/06/10) adjust the research and development strategy Lingbei or will lay off 160 people; hope of the new crown patients: The Chinese team to develop new drugs approved by the FDA into Clinical Phase III; "Insulin One Brother" status is not guaranteed? A number of pharmaceutical companies are snapping up the $25 billion market9, Lundbeck announced plans to change and optimize its research and development organization to enhance the company's ability to strengthen and advance its product lines at all stages in the field of neuroscience, and could lead to about 130-160 job cuts at its research and development centerOrchard will save about $125 million by the end of 2021CD24Fc fusion protein, from theoretical research to the new drug PHASE III clinical, has been nearly 30 years of historyIt is mainly by inhibiting the natural immune response caused by tissue damage caused by the new coronavirus, to cope with the complex pathological process of new coronary pneumonia, so as to achieve the purpose of treatmentRandomized double-blind trials for patients with new coronary disease are being rapidly advancedCD24Fc can make the new crown virus less scarythe eight ASCO conferences held between 2013 and 2020 are only one-seven th in ASCO's history, but it is a transformation from its debut to the hottest field of cancer research for immunotherapyOn the big stage of ASCO, a number of research breakthroughs in immunotherapy have been announced around the world, and some key results have rewritten the pattern of cancer therapyThe progress of basic research and the breakthrough of clinical research are closely related to the success of the commercial value of drugs, and the "knife and lightsaber shadow" on ASCO reflects the position of the major pharmaceutical companies in the "tumor" drug research and development commanding point and the commercial market gold trackwho can find the "blank spot" of the K drug in the immunotherapy layoutdays ago, the domestic insulin leader Gan Li Pharmaceuticals was issued by the Securities and Futures Commission IPO approval, causing market concern, which means that the official landing of A shares is close at handIn addition, The Recombinant Human Insulin Injection, the first insulin product of Dongsun Pharmaceuticals, was approved for saleBehind a series of "actions", the domestic insulin market may make waves againAccording to Minnet.com, sales of insulin and its similar drugs at the end of China's public medical institutions in 2019 were nearly 25 billion yuandiabetes prevalence is a global problemon June 8, , according to Tencent News Client's media account, another Tianji pharmacy opened in Wanshan, Fuyang, the fourth pharmacy opened in Wanshan, and each of the four pharmacies was less than 100 meters apart According to the media feedback, in this less than 500 meters of the street, there are 11 pharmacies, in addition to the Four pharmacies opened by Tianji Pharmacy, the single-life large pharmacy has three, the unified pharmacy has two, and two are monomers open1 pharmacies on a 500-metre street? , June 3, 2020, BTK inhibitor Zebutini, developed by Baiji Shenzhou, was approved by the China Food and Drug Administration for the treatment of adult set cell lymphoma patients who have previously received at least one treatment, as well as adult chronic lymphoblastic leukemia/small lymphocytic lymphoma patients who have previously received at least one treatment Zebbutini's molecular structure follows the path of innovation $82 billion! This is the top 10 pharmaceutical companies in the world in research and development spending in 2019, with total research and development spending on innovative drug development, diagnostics and vaccines, an increase of about $4 billion over 2018 cancer treatment remains the largest funding today motheton announced that its PD-1 antibody Keytruda failed to beat the OS and PFS in patients with advanced bladder cancer in patients with chemotherapy in the background of standard chemotherapy The trial, called KEYNOTE-361, recruited 1,010 patients with advanced bladder cancer using K-drug prescriptions, platinum standard chemotherapy, and combination therapy, with primary endpoints OS and PFS Although combination therapy improved both indicators, the distinction failed to achieve statistically significant results there is no formal statistical analysis of the advantages of unilateral K-drug recently, in the National Science Review, Yu Xiuwu and others published a research paper entitled "Autopsy of COVID-19 victims in China", a total of 91 cases of new crown pneumonia patients autopsy results summarized, of which 37 cases for systematic autopsies, 54 cases for minimally invasive autopsies, from the number of the world's largest new coronavirus pneumonia autopsy report The leading cause of death in patients is multi-organ dysfunction syndrome.